Safety and efficacy of a novel short occlusive regimen of imiquimod for selected non-melanotic skin lesions in renal transplant patients

G Das; B Tan; K Nicholls

doi:10.1111/imj.13004

Safety and efficacy of a novel short occlusive regimen of imiquimod for selected non-melanotic skin lesions in renal transplant patients

Intern Med J. 2016 Mar;46(3):352-5. doi: 10.1111/imj.13004.

Authors

G Das¹, B Tan², K Nicholls^{1

3}

Affiliations

¹ Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
² Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
³ Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

PMID: 26968597
DOI: 10.1111/imj.13004

Abstract

Australian patients remain at very high risk of non-melanotic skin cancer after renal transplantation. Surgical excision offers a cure but destroys tissue and may jeopardise function and cosmesis. We report excellent safety and efficacy using topical imiquimod in a novel short intensive regimen in 10 renal transplant patients with superficial basal cell carcinomas, Bowen disease or actinic keratosis. Outcomes compare well to those reported with extended-use imiquimod protocols.

Keywords: BCC; Bowen disease; actinic keratoses; imiquimod; non-melanotic skin cancer; renal transplant.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aminoquinolines / administration & dosage*
Aminoquinolines / adverse effects*
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects*
Australia / epidemiology
Female
Humans
Imiquimod
Kidney Transplantation / adverse effects*
Male
Middle Aged
Retrospective Studies
Skin Neoplasms / diagnosis
Skin Neoplasms / drug therapy*
Skin Neoplasms / epidemiology
Time Factors
Treatment Outcome

Substances

Aminoquinolines
Antineoplastic Agents
Imiquimod